Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Invests $16.83 Million in Insmed Incorporated (NASDAQ:INSM)

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 243,748 shares of the biopharmaceutical company's stock, valued at approximately $16,828,000. Insmed makes up approximately 2.0% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s portfolio, making the stock its 23rd biggest position. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned 0.14% of Insmed as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Steward Partners Investment Advisory LLC boosted its stake in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 163 shares in the last quarter. V Square Quantitative Management LLC boosted its holdings in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 248 shares during the last quarter. Spire Wealth Management purchased a new position in Insmed during the fourth quarter valued at approximately $47,000. Smartleaf Asset Management LLC lifted its stake in shares of Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 411 shares during the period. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Insmed during the 4th quarter worth about $86,000.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Jefferies Financial Group initiated coverage on shares of Insmed in a research report on Tuesday, May 13th. They set a "buy" rating and a $105.00 price target for the company. Royal Bank of Canada restated an "outperform" rating and issued a $100.00 target price on shares of Insmed in a report on Wednesday, March 19th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Bank of America upped their price target on Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research note on Thursday, March 20th. Finally, Morgan Stanley lifted their target price on Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, Insmed has an average rating of "Moderate Buy" and an average target price of $94.63.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $67.88 on Tuesday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The stock has a 50 day simple moving average of $71.45 and a 200-day simple moving average of $73.16. The company has a market cap of $12.36 billion, a PE ratio of -12.14 and a beta of 0.84.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. During the same period in the previous year, the company posted ($1.06) earnings per share. Insmed's revenue was up 22.9% compared to the same quarter last year. On average, equities research analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 18,750 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $77.79, for a total transaction of $1,458,562.50. Following the completion of the transaction, the chief executive officer now owns 334,186 shares in the company, valued at $25,996,328.94. This trade represents a 5.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Michael Alexander Smith sold 4,407 shares of Insmed stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $67.81, for a total value of $298,838.67. Following the transaction, the insider now directly owns 92,203 shares of the company's stock, valued at approximately $6,252,285.43. The trade was a 4.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 125,211 shares of company stock worth $8,837,158. Insiders own 3.00% of the company's stock.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.